In vitro studies from the same group revealed that the miR-30-embedded shRNA silencing vector successfully decreased α-synuclein levels (Han et al., 2011); yet delivery of AAV-mir30-hSNCA in the rat brain did not produce encouraging results towards a potential PD therapy (Khodr et al., 2014). Here, SNCA is linked to Parkinson disease.